Background: Respiratory infections are a cause of socio-health concern due to their high mortality and the economic cost. The number of patients from social care centers with respiratory infections requiring hospital admission is increasing in recent decades. The particularities of these patients could influence the evolution of these infections.
Aim: To analyze if there are differences respect to mortality between respiratory infections of community origin and those associated with social care centers.
Methods: A systematic review was carried out in three databases: Medline, Web of Science and Scopus. Empirical studies, published between 2000 and 2016, were included.
Results: The origin of the patients, age and malnutrition were the factors associated with worse prognosis, together with the presence of cardiac or neurological comorbidity. Mortality was higher in patients from social care centers compared to those who came from their home.
Conclusion: Health professionals should take into account the origin of the patients in order to give a more personalized care according to the particularities of these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/S0716-10182019000600716 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFBackground: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.
My back hurts! Did you have COVID-19 infection?
Agri
January 2025
Department of Algology, Ministry of Health Ankara Etlik City Hospital, Ankara, Türkiye.
Pain may be an early symptom of COVID-19 infection, most commonly seen as myalgia and headache. However, atypical presentations such as abdominal pain and leg pain can also be observed. We present seven cases of COVID-19 treated for pain.
View Article and Find Full Text PDFSelf-reported perceptions of adults with diabetes regarding their care and health in the time of COVID-19 pandemic in a Swiss region: a cross-sectional study.
Swiss Med Wkly
December 2024
Center for Primary Care and Public Health (Unisanté), Department of Epidemiology and Health Systems, University of Lausanne, Lausanne, Switzerland.
Aim: To assess the perceptions of adults with diabetes regarding their care and health during the COVID-19 pandemic in the canton of Vaud, Switzerland.
Methods: Cross-sectional data was analysed from the 2021 follow-up questionnaire of the CoDiab-VD survey, a cohort of adults living with diabetes in the canton of Vaud. Various aspects of diabetes care and issues relating to the COVID-19 pandemic were assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!